Renate Pagel
Family · Gainesville, TXNPI 1811475247
Payments from drug & device makers
Across 67 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$327
- AstraZeneca$223
- Boehringer Ingelheim$94
- Lilly USA, LLC$78
- Mylan Specialty L.p.$49
- Exact Sciences$30
- plus $363 from 20 others
What the payments were for
- Food & beverage$1,164100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $327 |
| AstraZeneca | 10 | $223 |
| Boehringer Ingelheim | 6 | $94 |
| Lilly USA, LLC | 5 | $78 |
| Mylan Specialty L.p. | 2 | $49 |
| Exact Sciences | 2 | $30 |
| Shield Therapeutics Inc | 1 | $28 |
| Astellas Pharma US Inc | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| GSK | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| Halozyme Inc | 1 | $19 |
| Vertex | 1 | $17 |
| Pfizer | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| AbbVie | 1 | $15 |
| Novartis | 1 | $14 |
| Viatris Specialty LLC | 1 | $14 |
| Amgen | 1 | $14 |
How this compares
$1,164 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $34,987 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $10,395 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,344 |
| Azithromycin | 103 | $528 |
| Lisinopril | 63 | $523 |
| Levothyroxine Sodium | 79 | $512 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 45 | $511 |
| Gabapentin | 33 | $475 |
| Trazodone Hcl | 37 | $410 |
| Ondansetron OdtOndansetron | 28 | $402 |
| Escitalopram Oxalate | 26 | $399 |
| Amlodipine Besylate | 64 | $390 |
| Duloxetine Hcl | 19 | $358 |
| Cyclobenzaprine Hcl | 37 | $327 |
| Ropinirole Hcl | 25 | $322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $327 | $34,98728 claims |
| GSKTrelegy Ellipta | $20 | $10,39514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.
Other family in Gainesville
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.